Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
6 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Marker Therapeutics, Inc.’s names, not what it holds today.
Patents granted
6
6 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
12
since 2001, to Dec 31, 2025
Names they are printed under
3
a former name, its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name3 counted
TapImmune Inc. a former name
US, as the owner printed on each patent. 3 more under the same name are not counted (printed in CA)
3 publishedTapImmune Inc. a former name
named as the applicant on its applications, in US
6 publishedMARKER THERAPEUTICS INC. its own name
named as the applicant on its applications, in US
3 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 24, 2018 | 10,030,252 | Chimeric nucleic acid molecules with non-AUG translation initiation sequences and uses thereof | Pharmaceuticals | TapImmune Inc. |
| Jun 5, 2018 | 9,988,643 | Chimeric nucleic acid molecules with non-AUG translation initiation sequences and uses thereof | Pharmaceuticals | TapImmune Inc. |
| May 23, 2017 | 9,655,956 | Chimeric nucleic acid molecules with non-AUG translation initiation sequences and uses thereof | Pharmaceuticals | TapImmune Inc. |
| Jun 14, 2016 | 9,364,523 | Chimeric nucleic acid molecule with non-AUG translation initiation sequences | Pharmaceuticals | TapImmune Inc. |
| Aug 9, 2011 | 7,994,146 | Method of enhancing an immune response | Pharmaceuticals | TapImmune Inc. |
| Jul 12, 2011 | 7,976,850 | Pox viridae treatment | Pharmaceuticals | TapImmune Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 5, 2024 | 2024/0400992 | COMPOSITIONS AND METHODS FOR ANTIGEN-SPECIFIC T CELL EXPANSION | Biotechnology | MARKER THERAPEUTICS INC. |
| Feb 24, 2022 | 2022/0056473 | CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF | Pharmaceuticals | MARKER THERAPEUTICS INC. |
| Feb 3, 2022 | 2022/0033844 | CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF | Pharmaceuticals | MARKER THERAPEUTICS INC. |
| Aug 16, 2018 | 2018/0230487 | CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF | Pharmaceuticals | TapImmune Inc. |
| Jun 14, 2018 | 2018/0163226 | CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF | Pharmaceuticals | TapImmune Inc. |
| Jan 19, 2017 | 2017/0016026 | CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF | Pharmaceuticals | TapImmune Inc. · patent 10,030,252 granted from it |
| Dec 22, 2016 | 2016/0367652 | CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF | Pharmaceuticals | TapImmune Inc. · patent 9,655,956 granted from it |
| Dec 8, 2016 | 2016/0354455 | CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF | Pharmaceuticals | TapImmune Inc. · patent 9,988,643 granted from it |
| Sep 17, 2015 | 2015/0258186 | NUCLEIC ACID MOLECULE VACCINE COMPOSITIONS AND USES THEREOF | Pharmaceuticals | TapImmune Inc. · patent 9,364,523 granted from it |
| May 31, 2012 | 2012/0135031 | METHOD OF ENHANCING AN IMMUNE RESPONSE | Pharmaceuticals | TapImmune Inc. |
What it applied for, 2024 to 2025: Biotechnology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.